US Children's Bureau

New Capabilities

Sponsor of BE BOLD and maker of bimekizumab (BIMZELX)

Bimekizumab produced higher joint-response rates than risankizumab in psoriatic arthritis, and the gap held at every measured timepoint through Week 24. At Week 24, 54.9% of patients on bimekizumab reached ACR50 against 43.8% on risankizumab.

Updated 2 days ago

New Capabilities

Developer and marketer of ZILBRYSQ

Adults with generalized myasthenia gravis (gMG, a disease that weakens voluntary muscles) can now take their daily Zilbrysq dose with a spring-loaded autoinjector instead of a prefilled syringe. The FDA approved the device on October 16. In a study of 100 people, 90% completed a first injection with no training.

Updated Oct 27

New Capabilities

As of May 2026: Now part of Administration for Children and Families; Maternal and Child Health Bureau continues its work

In 1900, one in seven babies born in the United States or United Kingdom died before their first birthday. By 2017, the rate had fallen to roughly 4-6 per 1,000—a decline exceeding 95%. This transformed how families experience childbirth and early childhood.

Updated May 22